Correcting a Low Bicarbonate That Might Just Be a Marker
A CKD patient's serum bicarbonate has drifted into mild acidosis. Whether treating that number actually slows her disease, or only treats a downstream marker of how far the disease has already gone, is a question the guidelines themselves decline to fully answer.
Two consecutive metabolic panels showing the same low bicarbonate are what prompted today's conversation about Eleanor P. She is a 74-year-old woman who retired eight years ago after four decades as a public librarian, and still volunteers shelving returns two mornings a week — work she says keeps her "on a schedule that matters to someone besides me." Her CKD, stage 4 with an eGFR of 24, has been followed for six years, attributed to a combination of longstanding hypertension and an episode of acute kidney injury after a hip surgery in her sixties that never fully resolved. Both readings came in at 17 to 18 mEq/L — mild-to-moderate metabolic acidosis, the kind that produces no symptoms she'd notice but that nephrology has flagged as worth addressing before it becomes a louder problem.
The evidence for treating it directly is real but genuinely contested. De Brito-Ashurst and colleagues' 2009 randomized trial found that sodium bicarbonate supplementation in CKD patients with metabolic acidosis slowed the rate of eGFR decline and reduced progression to needing dialysis compared to standard care alone. What KDIGO's own current guidance reflects, though, is that several subsequent trials attempting to confirm that finding on hard renal outcomes have produced more mixed results — enough that the recommendation to correct bicarbonate in CKD is written as a practice point rather than a graded, strongly-evidenced recommendation. Whether the acidosis itself is driving her progression, or is simply a marker of how far her disease has already traveled, isn't settled either way. What is concrete is the cost of correcting it: typical bicarbonate dosing adds roughly two to four grams of sodium daily, in a patient whose blood pressure has needed three medications to control.
A bicarbonate of 17, and what correcting it would actually cost
Start sodium bicarbonate. De Brito-Ashurst's trial found a real slowing of eGFR decline and fewer patients reaching dialysis with correction, and acidosis has its own independent cost regardless of what it does to her renal trajectory — it drives protein catabolism, and muscle wasting in a 74-year-old is not a trivial side effect to accept for the sake of avoiding a pill.
Worth being direct about why KDIGO wrote this as a practice point rather than a graded recommendation: the trials that followed de Brito-Ashurst's, larger and attempting to confirm the hard renal-outcome benefit, produced more mixed results, and whether acidosis is actually driving her decline or just marking how far it's already gone isn't resolved either way. Typical dosing adds two to four grams of sodium daily — a real number against blood pressure that already needs three drugs and still isn't quite at goal.
I'm not arguing the catabolic cost of acidosis is fictional, only that we shouldn't treat the progression-slowing case as more settled than KDIGO's own language reflects it to be.
These positions converge more than they look like they do. A conservative dose aimed at partial correction — bicarbonate toward 20 to 22, not fully normalized — captures most of the anti-catabolic benefit without asking for the full sodium load a complete correction would require, and we can watch her blood pressure directly over the next month rather than deciding in advance that the sodium concern will materialize. If it does, we've lost little; if it doesn't, she's kept the benefit at lower cost either way.
Agreed: a conservative bicarbonate dose started, blood pressure checked at home twice weekly, and basic metabolic panel repeated at one month to confirm the correction is heading toward, not past, the intended partial target.
Not resolved, and stated as such rather than smoothed over: whether the underlying question — is acidosis itself accelerating her decline, or only marking it — will ever be answerable for Eleanor specifically, regardless of what her own bicarbonate does over the coming months.